Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule with the chemical formula C23H24FN3O2 and a molecular weight of approximately 393.46 g/mol[1][3]. It is a quinazolinone derivative featuring a fluorine atom at position five and a butyl-linked phenyl dihydropyridine moiety. The compound has been referenced in chemical databases as FRQ and PD005033[7]. There are no approved medical indications or clinical trials associated with this drug as of now[4]. Mechanistically, it has been identified in structural studies as binding to poly [ADP-ribose] polymerase enzymes (PARP), specifically PARP1 and PARP2[3], suggesting potential activity as a PARP inhibitor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-fluoro-1-[4-(4-phenyl-3,6-dihydropyridin-1(2h)-yl)butyl]quinazoline-2,4(1h,3h)-dione.